A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

NCT02385669 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped why study stopped

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
BIOLOGICAL: 6MHP

Sponsor

Craig L Slingluff, Jr